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Abstract
 
A recently identiﬁed G to A mutation at the last nu-
cleotide of exon 6 of the sterol 27-hydroxylase gene (
 
CYP
 
 27)
in a patient with cerebrotendinous xanthomatosis (CTX) was
shown here to cause alternative pre-mRNA splicing of the
gene. Northern blot analysis of the patient’s RNA revealed a
broadened band in the human 
 
CYP
 
 27 mRNA region com-
pared to that of the normal sample, indicating that there may
exist differently spliced mRNA species in the patient. RT-PCR
produced three fragments in the patient, one was full-length
size and the other two were of smaller sizes. Sequence analysis
conﬁrmed that the nucleotide of the full-length size was iden-
tical to that of the normal full-length cDNA, except for the G
to A mutation at codon 362, which corresponds to the last nu-
cleotide of exon 6. One of the smaller size species lacked
exon 6 and the other was absent from the 3
 
9
 
 terminal 88 bp of
exon 6 due to the use of an activated cryptic 5
 
9
 
 splice site
in exon 6. The correctly spliced mRNA harbouring the G to A
mutation was responsible for the deﬁciency of the sterol 27-
hydroxylase activity, as conﬁrmed by transfection experiment.
Transfection of constructed minigenes, with or without the
mutation, showed that correctly spliced mRNA was observed
in the normal minigene while the mutant minigene was dif-
ferently spliced.  This is the ﬁrst report of a G to A substitu-
tion at the last nucleotide of an exon resulting in both normal
and abnormal pre-mRNA splicings, including exon skipping
and activating of a coding region cryptic 5
 
9
 
 splice site. The re-
sults reveal a new molecular basis for the CTX and provide in-
formation on aberrant splicing of pre-mRNA in multi-exon
genes. 
 
—Chen, W., S. Kubota, and Y. Seyama.
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Sterol 27-hydroxylase is a mitochondrial P-450 en-
zyme that catalyzes the initial step in the hepatic oxida-
 
tion of the side chain of sterol intermediates in the
pathway for metabolism and biliary excretion of choles-
terol (1). Mutations in the sterol 27-hydroxylase gene
(
 
CYP 
 
27) cause cerebrotendinous xanthomatosis (CTX),
an autosomal recessively inherited cholesterol meta-
bolic disorder characterized by tendon xanthomatosis,
cataracts, neurological manifestations, osteoporosis,
and premature atherosclerosis. Since the cloning of hu-
man sterol 27-hydroxylase cDNA (2) and determina-
tion of its genomic structure (3), several mutations of
the sterol 27-hydroxylase gene have been identiﬁed in
CTX patients from different countries (4–12). Most of
the mutations reported to date are point mutations
that lead to amino acid substitution or premature ter-
mination codon.
Study of de novo mutations that occur at splice site
regions in many inherited diseases contributes greatly
to understanding of the mechanisms of normal pre-
mRNA splicing. A number of mutations at the abso-
lutely conserved intronic 5
 
9
 
 gt or 3
 
9
 
 ag dinucleotide at
splice sites have been identiﬁed in various genetic dis-
eases. Mutations at these sites usually lead to aberrant
pre-mRNA splicing or abolish normal pre-mRNA tran-
scription (13–15). On the other hand, mutations at the
moderately conserved 
 
2
 
1 position G of a 5
 
9
 
 splice site
(corresponds to the last nucleotide of an exon) are rel-
atively rare and the effect of these mutations on the
pre-mRNA splicing has been given less attention.
 
Abbreviations: CTX, cerebrotendinous xanthomatosis; 
 
CYP
 
 27 gene,
sterol 27-hydroxylase gene; pre-mRNA, precursor messenger RNA; RT-
PCR, reverse transcription polymerase chain reaction; HPLC, high per-
formance liquid chromatography; CPS, count per second.
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We report here the ﬁrst example of a G to A substitu-
tion at the last nucleotide of exon 6 in the 
 
CYP
 
 27 gene
that leads to alternative splicings of pre-mRNA, includ-
ing exon 6 skipping, activating of a coding region cryp-
tic 5
 
9
 
 splice site, and also correct splicing of pre-mRNA
carrying the G to A mutation. We analyzed the tran-
scription products of this mutant gene in vivo and con-
ﬁrmed that the aberrant pre-mRNA splicings were
caused by the mutation in vitro.
MATERIALS AND METHODS
 
Subject
 
A 24-year-old female Japanese CTX patient was stud-
ied. The patient complained of gradually enlarging bi-
lateral Achilles tendons as well as similar subcutaneous
swellings over her triceps, knees, and dextral 2nd ﬁn-
ger joint when we examined her at the age of 17. Mild
mental retardation with an IQ of 67 was conﬁrmed. No
other remarkable neurological defects and visual im-
pairment could be found. Cardiovascular investigations
were also normal. Biochemical analysis showed a mark-
edly elevated plasma cholestanol concentration of 40.6
 
m
 
g/ml. No sterol 27-hydroxylase activity was detected
in the ﬁbroblasts from the patient.
 
Northern blot analysis
 
Thirty 
 
m
 
g total RNA extracted from cultured ﬁbro-
blasts derived from a healthy subject and from the pa-
tient was separated by electrophoresis in a 1.6% formal-
dehyde agarose gel and transferred to a positively
charged nylon membrane (Boehringer Mannheim,
Mannheim, Germany). After prehybridization in high
SDS concentration buffer (7% SDS, 50 m
 
m
 
 sodium
phosphate, pH 7.0, 50% formamide, 2% blocking re-
agent, 50 
 
m
 
g/ml transfer yeast RNA, 5
 
3
 
 SSC, 0.1% lau-
roylsarcosine) at 50
 
8
 
C for 24 h, the membrane was hy-
bridized at 50
 
8
 
C for 48 h with the full-length sterol 27-
hydroxylase cDNA probe or 
 
b
 
-actin probe (243 bp, nu-
cleotide 143–385 in human 
 
b
 
-actin cDNA) labeled with
digoxigenin-11-dUTP by the random primed method
according to the manufacturer’s instructions (Boe-
hringer Mannheim). Detection was performed with
colorimetric detection reagents from Boehringer Man-
nheim. Quantitative analysis was carried out by normal-
izing the signals to that of the 
 
b
 
-actin RNA control us-
ing the software, NIH Image, 1.61.
 
Full-length cDNA ampliﬁcation of the
sterol 27-hydroxylase gene
 
To amplify the full-length cDNA of the sterol 27-
hydroxylase gene, 1 
 
m
 
g total RNA was ﬁrst converted to
cDNA in a 20 
 
m
 
l reaction mixture containing 5 m
 
m
 
MgCl
 
2
 
, 1 
 
3
 
 PCR buffer II (10 m
 
m
 
 Tris-HCl, pH 8.3; 50
m
 
m
 
 KCl), 1 m
 
m
 
 of each dNTP, 1 U RNase inhibitor, 1
 
m
 
m
 
 oligonucleotide dT and 5 U reverse transcriptase,
using a RT-PCR kit (TaKaRa, Otsu City, Japan). The re-
action tube was incubated at 42
 
8
 
C for 60 min (anneal-
ing and extension), heated at 95
 
8
 
C for 5 min (inactiva-
tion of reverse transcriptase and denaturation of RNA-
cDNA hybrids), and then soaked at 5
 
8
 
C for 5 min in a
thermal cycler (Perkin Elmer, GeneAmp PCR system
9600). PCR ampliﬁcation was immediately performed
after the RT reaction by adding 80 
 
m
 
l of a PCR Master
Mix containing 1.25 m
 
m
 
 MgCl
 
2
 
, 1 
 
3
 
 PCR buffer II, 0.25
 
m
 
m
 
 upstream primer FLup (nucleotide: 20–40, 5
 
9
 
CCATGGCTGCGCTGGGCTGCG3
 
9
 
) and downstream
primer FLd (nucleotide: 1639–1618, 5
 
9
 
CCCAGCAAG
GCGGAGACTCAGC3
 
9
 
), 11.4 
 
m
 
l DMSO, and 2.5 U Taq
DNA polymerase. The ampliﬁcation reaction was per-
formed for 30 cycles under the following conditions:
1.5 min at 95
 
8
 
C for denaturation, 30 sec at 68
 
8
 
C for
annealing, and 2 min (4 sec increment every successive
cycle) at 72
 
8
 
C for extension. Electrophoresis was per-
formed on a 2% agarose gel. Quantitative analysis was
carried out by scanning the gel, and the density of
the bands was analyzed using the software, NIH Image,
1.61. 
 
b
 
-Actin was ampliﬁed as a control for quantita-
tive analysis.
 
Sequence analysis
 
DNA sequence analysis was performed using the ABI
PRISM™ 310 Genetical Analyzer as described previ-
ously (16). Brieﬂy, either the PCR product or plasmid
was ﬁrst labeled by Taq terminator sequencing reaction
in a thermal cycler, under the following condition:
96
 
8
 
C for 10 sec, 50
 
8
 
C for 5 sec, and 60
 
8
 
C for 4 min for a
total 25 cycles. After removing the excess unincorpo-
rated terminators using the Centri-Sep Spin column
(ABI, Foster, CA), according to the manufacturer’s pro-
tocol, the labeled products were dried, resuspended in
25 
 
m
 
l Template Suppression Reaction, and heated to
92
 
8
 
C for 2 min for denaturation. Then, the samples
were loaded on an ABI PRISM™ 310 Genetical Ana-
lyzer for sequence analysis. All of the ﬂuorescein se-
quencing reagents were purchased from ABI. All the
samples were sequenced in both directions in order to
conﬁrm the identiﬁed mutations. The primers used for
sequencing were: FLup (nucleotide: 20–40, 5
 
9
 
CCA
TGGCTGCGCTGGGCTGCG3
 
9
 
), P357 (nucleotide: 382–
402, 5
 
9
 
GAGGGAAAGTACCCAGTACGG3
 
9
 
), P359 (nu-
cleotide: 737–758, 5
 
9
 
CCTTCGTCAGATCCATCGGGTT
3
 
9
 
), P372 (nucleotide: 1159–1181, 5
 
9
 
TTTGCCCACATG
CCGTTGCTCAA3
 
9
 
), and FLd (nucleotide: 1639–1618,
5
 
9
 
CCCAGCAAGGCGGAGACTCAGC3
 
9
 
. 
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Construction of expression vector
 
To observe the different splicing patterns caused by the
G to A mutation at the last nucleotide of exon 6, two mini-
gene constructs, with or without the mutation, were gen-
erated and transfected into COS cells. Genomic se-
quences from exon 5 to exon 9 of the 
 
CYP
 
 27 gene was
ampliﬁed from the patient and a healthy subject using
primers SPup 5
 
9
 
CGAAGATATGGAGGCCCAACT3
 
9
 
 (nu-
cleotide: 891–911) and SPd 5
 
9
 
TCAGCACTGTCTCT
GCAGGAAC3
 
9
 
 (nucleotide: 1596–1617). The PCR ampli-
ﬁcation reaction was performed for 30 cycles under the
following conditions: 1 min at 95
 
8
 
C for denaturation and
4 min at 68
 
8
 
C for annealing and extension. The upstream
primer SPup contains an initial codon ATG and the 
 
2
 
3
position relative to the ATG is a G which is considered to
ensure efﬁcient translation (17). The downstream primer
SPd contains the stop codon TGA. After conﬁrmation of
successful ampliﬁcation of the 2111 bp band by agarose
gel electrophoresis, the insert was directly ligated into the
pTARGET™ expression vector (Promega, Madison, WI)
which contains CMV immediate-early enhancer/pro-
moter region, a chimeric intron for high level expression
of insert, and the SV40 late polyadenylation signal. Plas-
mids of the minigene constructs were prepared using
JETSTAR Plasmid Kit (Genomed, Research Triangle
Park, NC). The two minigenes have the same structure ex-
cept for the G to A mutation at the last nucleotide of exon
6, as conﬁrmed by sequence analysis.
 
Creation of mutant full-length cDNA by in vitro
site-directed mutagenesis
 
For expression analysis of the mutant full-length cDNA,
the G to A mutation was recreated in an expressible cDNA
encoding human sterol 27-hydroxylase. Site-directed mu-
tagenesis of the cDNA was accomplished using the
pKF18k vector and a kit from TaKaRa. Then, the normal
and mutant cDNAs of the sterol 27-hydroxylase were li-
gated into the pTARGET™ expression vector by 
 
Eco
 
R I
sites. The nucleotide sequences of the normal and mutant
cDNAs were conﬁrmed by sequence analysis. Plasmids for
transfection were prepared using a JETSTAR Plasmid Kit.
 
Transfection analysis
 
COS-1 cells obtained from JCRB cell Bank (Tokyo,
Japan) were maintained in DMEM containing 10%
fetal calf serum and used for transfection. Twenty 
 
m
 
g
plasmids of the normal and mutant minigene con-
structs and a mock vector were transfected in triplicate
into 1 
 
3
 
 10
 
6
 
 COS cells by the method of calcium phos-
phate co-precipitation. Forty-eight hours after transfec-
tion, total RNA was extracted by acid guanidine–phenol–
chloroform method and used for RT-PCR analysis to
conﬁrm the splicing patterns. Electrophoresis was per-
formed on a 5% acrylamide gel.
To determine the effect of the G to A mutation on
the sterol 27-hydroxylase activity, 20 
 
m
 
g plasmids carry-
ing normal cDNA or mutant cDNA were transfected in
triplicate into 1 
 
3
 
 10
 
6
 
 cells, as described above. After 48
h, cells were harvested and the mitochondrial fraction
was prepared, as described (5). The isolated mitochon-
drial fraction was used for sterol 27-hydroxylase assay.
 
Assay of sterol 27-hydroxylase activity
 
Assay of sterol 27-hydroxylase activity was performed
using a procedure described by Skrede et al. (18). La-
beled substrate, 5
 
b
 
-[7
 
b
 
-
 
3
 
H]cholestane-3
 
a
 
,7
 
a
 
,12
 
a
 
-triol
with speciﬁc activity 150 cpm/pmol was synthesized as
described and puriﬁed by HPLC (19). The substrate
(480,000 cpm, 3.2 nmol) was dissolved in 10 
 
m
 
l acetone
(which was then evaporated under a nitrogen stream),
and solubilized in 250 
 
m
 
l of 5% bovine serum albumin
followed by the addition of the following incubation
mixture: 33 m
 
m
 
 HEPES (pH 7.4); 5 m
 
m
 
 ATP; 5 m
 
m
 
potassium malate; 1 m
 
m
 
 glucose 6-phosphate; 0.5 IU
glucose-6-phosphate dehydrogenase; 1.2 m
 
m 
 
NADPH,
and 15 m
 
m
 
 MgCl
 
2. The mitochondrial pellet isolated
from the transfected COS cells was suspended in 250 ml
of 0.25 m sucrose and added to the incubation mixture
to start the reaction, giving a ﬁnal volume of 608 ml.
After incubation at 378C for 1 h, the reaction was termi-
nated by adding 0.1 ml 1 m HCl. Extraction with 5 ml
ethylacetate was performed twice and the converted 27-
hydroxylated product was detected by HPLC (LC-10A
Shimadzu, Kyoto, Japan) using an LC-18 column (250 3
4.6 mm, Supelco, Bellefonte, PA). The radioactivity of
the product was measured using a radiodetector (RLC-
700, Aloka, Tokyo, Japan).
RESULTS
Mutation of the CYP 27 gene in the CTX patient
We recently identiﬁed a G to A substitution at the last
nucleotide of exon 6 in the patient (20). The same mu-
tation was conﬁrmed this time by Taq terminator se-
quencing reaction on the ABI PRISM™ 310 Genetical
Analyzer. Except for this nucleotide change, the se-
quences of all 9 exons, splice site regions, and pro-
moter region in the patient were identical to that in the
healthy subject (data not shown).
Transcription analysis of the mutant gene
in vivo and in vitro
As the mutation occurred at the last nucleotide of
exon 6, its effect on pre-mRNA transcription was ﬁrst
analyzed in vivo. Northern blot analysis of the patient’s512 Journal of Lipid Research Volume 39, 1998
RNA showed a broadened band compared to that in
the normal sample (2.2 kb), indicating that there may
exist differently spliced mRNA species (Fig. 1). No ob-
vious decrease of transcription efﬁciency was observed
in the patient (0.90) compared to that in the normal
sample (0.97) as determined by quantitative analysis of
the signals.
We next performed RT-PCR for the CYP 27 gene us-
ing RNAs derived from the patient and a healthy sub-
ject. Similar results were obtained in three separate ex-
periments. One typical example is shown in Fig. 2. In
the patient’s full-length RT-PCR product, two smaller
fragments were observed in addition to the normal size
fragment compared to that in the normal sample (Fig. 2).
The ratio of the three species was 1:0.84:0.16 (normal
size:middle size:the smallest size) by quantitative analy-
sis as described in Materials and Methods. The amount
of normal size in the patient accounted for 54.1% of
that in the healthy subject as determined by quantita-
tive analysis. The b-actin RT-PCR product was used for
correction of the quantitation. Each of the RT-PCR
products was subcloned into pTARGET™ vector. Se-
quence analysis of the subcloned RT-PCR product re-
vealed three species of different insert sizes in the pa-
tient: full-length cDNA carrying the G to A substitution
at codon 362 (CGT 362Arg to CAT 362His) (Fig. 3B); 39
terminal 88 bp of exon 6 deleted-cDNA due to use of
an activated 59 splice site in exon 6 (Fig. 3C); and exon
6 skipped cDNA (Fig. 3D). The three types of cDNA
corresponded to the three fragments observed in elec-
trophoresis of the RT-PCR products (Fig. 2). No abnor-
mal cDNA inserted colony was found in the sample
from the healthy subject (data not shown).
To conﬁrm that the abnormal cDNA fragments were
generated by the alternative pre-mRNA splicing due to
the mutation, minigene constructs consisting of ge-
nome sequences form exon 5 to exon 9 of the CYP 27
gene, with or without the mutation, were transiently
transfected into COS cells. RT-PCR analysis of the total
RNA extracted from the transfected cells using primers
SPup and SPd showed a single 726 bp band in normal
minigene, while in the mutant minigene, the most
abundant band was 412 bp one, with 2 faint 560 bp and
638 bp bands (Fig. 4B). Sequence analysis conﬁrmed
that the single 726 bp band observed in the normal
minigene corresponded to the correctly spliced RNA
species. On the other hand, the major band observed
in the mutant minigene lacked exons 5 and 6, and one
of the faint bands was absent from exon 6 and the
other was absent from the 39 terminal 88 bp of exon 6
due to use of an activated 59 cryptic splice site (Fig. 4A).
Thus, the in vitro data conﬁrmed that the normal mini-
gene could be spliced correctly, while the G to A muta-
tion at the last nucleotide of exon 6 was responsible for
the abnormal pre-mRNA splicing.
Transfection analysis of the mutant full-length cDNA
Of the three species of spliced mRNA observed in
vivo in the patient (Fig. 2), the two smaller ones led to
frame-shift, and translations of these mRNAs synthe-
Fig. 1. Northern blot analysis of the sterol 27-hydroxylase
mRNA. Thirty mg total RNA extracted from cultured ﬁbroblasts
from a healthy subject and from the patient were separated by
electrophoresis in a 1.6% formaldehyde agarose gel and trans-
ferred to a positively charged nylon membrane. Hybridization was
carried out at 508C for 48 h with the full-length sterol 27-hydroxy-
lase cDNA probe labeled with digoxigenin-11-dUTP. Detection
was performed with colorimetric reaction. b-Actin was used as a
control.
Fig. 2. RT-PCR analysis of the sterol 27-hydroxylase mRNA. Full-
length cDNA of the CYP 27 gene was ampliﬁed as described in the
Materials and Methods. b-Actin mRNA was ampliﬁed at the same
time and used for correction of quantitative analysis. pHY DNA
marker was used.Chen, Kubota, and Seyama Pre-mRNA splicing of the CYP 27 gene in CTX 513
sized truncated sterol 27-hydroxylases lacking enzyme
activity. As correctly spliced mRNA harboring the G to
A mutation was also observed in the patient, its effect
on the sterol 27-hydroxylase activity was checked in a
transfection experiment. As shown in Fig. 5, transfec-
tion with a vector carrying the normal full-length cDNA
led to 10.6 6 1.7% (mean 6 SD) conversion of sub-
strate 5b-[7b-3H]cholestane-3a,7a,12a-triol into 27-hy-
droxylated product 5b-[7b-3H]cholestane-3a,7a,12a,
27-tetrol. In contrast, no converted substrate was de-
tected in COS cells transfected with the full-length
cDNA plasmid carrying the G to A mutation and a
mock plasmid. The results suggest that the mutation is
responsible for the deﬁciency of enzyme activity.
DISCUSSION
Although a G to C transversion at the last nucleotide
of exon 3 (21 position of the 59 splice site of intron 3)
in the CYP 27 gene has been reported (9), this muta-
Fig. 3. Sequence analysis of the subcloned full-length RT-PCR product. Full-length RT-PCR products
ampliﬁed from RNAs derived from the patient and a healthy subject were subcloned into pTARGET™
vector. Plasmids were prepared from colonies and sequenced. A: normal sample; B, C, D: patient sample.514 Journal of Lipid Research Volume 39, 1998
tion was only associated with a barely detectable level of
mRNA and no alternatively spliced mRNA species was
found. To our knowledge, no alternative splicing due
to the use of an activated 59 cryptic splice site in the
coding region has been reported in the eight cases with
G to A mutation  at the 21 position of a 59 splice site in
other genetic diseases (see below). The present muta-
tion is the ﬁrst example that a G to A mutation at the
last nucleotide of an exon resulted in both normal
splicing with the mutation and aberrant splicing, in-
cluding exon skipping and activating of a coding re-
gion cryptic 59 splice site. Transfection of the mini-
genes into COS cells conﬁrmed that the mutation led
to aberrant splicing in vitro. The different mRNA spe-
cies observed in vivo (Figs. 2 and 3) and in vitro (Fig. 4)
may result from different splicing conditions in vivo
and in vitro. It has been suggested that alternative splic-
ing in the cell could be modulated by subtle cell-
speciﬁc variations. Reed and Maniatis (21) observed that
splice site selection can sometimes be affected by dilut-
ing the splicing extract. Similar ﬁndings have also been
obtained by varying ionic conditions in the in vitro
splicing reaction (22). Weil et al. (23) reported that
temperature could effectively and speciﬁcally suppress
the expression of a splicing defect in the cell. These ob-
servations suggest that many factors are involved in the
splicing process that may affect the splicing pattern.
Early studies indicated that exon sequences may not
play a major role in RNA splicing (24). However, such a
notion has been challenged by more accurate investiga-
tions of sequence requirements using artiﬁcially gener-
ated RNA substrates that contain various combinations
and manipulations of cis-competing splice sites (21, 25,
26), and also by the accumulation of aberrant splicing
cases caused by de novo mutations in the exon region
of a splice site in some genetic diseases, as in the
present case. It is now widely accepted that pre-mRNA
splicing is carried out in a two-step process. First, the
pre-mRNA is cleaved at the 59 splice site with concomi-
tant joining of the 59 end of the intron by a 59–29 phos-
phodiester bond to a conserved A residue some 30–40
nucleotides upstream of the 39 splice site. Second, the
39 splice site is cleaved, releasing the intron as a
branched lariat, and the upstream exon is then joined
to the downstream exon (27–29). Although little is un-
Fig. 4. Transcription analysis of the mutant gene in vitro. Mini-
genes with or without the mutation were transfected into COS
cells. RNA was extracted from the transfected COS cells and RT-
PCR was performed to detect the alternative splicing. A: Scheme
of the minigene construct and the different splicing patterns. B:
RT-PCR analysis of RNA extracted from transfected COS cells.
0x174 Hae III DNA marker was used.
Fig. 5. Expression of normal and mutant full-length sterol 27-
hydroxylase cDNAs. COS cells were transfected with 20 mg of nor-
mal full-length cDNA plasmid, mutant full-length cDNA plasmid,
and mock plasmid by the calcium phosphate co-precipitation
method. After 48 h, the cells were harvested and the isolated mito-
chondrial fraction was used for assay of sterol 27-hydroxylase activ-
ity. The results shown were representative of two separate transfec-
tion experiments.Chen, Kubota, and Seyama Pre-mRNA splicing of the CYP 27 gene in CTX 515
derstood about how the different RNA regions involved
in this process are recognized and how precise cleavage
sites are determined, the sequence complementarity
between the consensus sequences around the splicing
sites and the small nuclear RNAs (snRNAs) is consid-
ered to be crucial for splicing (30). For example, U1 sn-
RNA is believed to recognize consensus sequences at
the 59 splice site (31). As shown in Fig. 6, the 59 termi-
nal single-strand nucleotides of U1 snRNA completely
base pair with the consensus 59 splice region of pre-
mRNA. The G to A mutation in our case disrupts one
of these base pairings and could be expected to reduce
the efﬁciency of normal splicing. In order to obtain
more precise information on the use of normal, mu-
tant, and cryptic 59 splice sites, we calculated the scores
of these splice sites according to Shapiro and Senapathy
(32). Scores of the mutant 59 splice site (CAgtaggt)
and the cryptic 59 splice site (TGGTGGGT) were 71.3
and 73.5, respectively, a little lower than the 75.4 of
normal 59 splice site of intron 6 (CGgtaggt). This may
explain the observation that three spliced mRNA spe-
cies exist simultaneously in our case. To date, only 11
mutations at the last nucleotide of exon have been
identiﬁed in some genetic diseases. The G to A substitu-
tion was reported in eight cases (23, 33–39) and G to C
(9, 40) and G to T (41, 42) were both reported twice.
Exon skipping was found in all of the eight G to A mu-
tant cases, and normal splicing carrying the mutation
was also observed in ﬁve of the eight cases. However, no
aberrant splicing due to use of an activated cryptic 59
splice site in a coding region was reported in any of the
G to A mutation cases. The present study is the ﬁrst ex-
ample that a G to A mutation occurring at the last nu-
cleotide of an exon can lead to aberrant splicing by use
of an activated 59 splice site in coding region. Different
from the mutation at the intronic 59 gt regions, which
usually blocks the normal 59 splice site (13–15), muta-
tion at the last nucleotide of exon at a 59 splice site does
not seem to block the normal 59 splice site completely.
G is present at the last nucleotide of exon in 78% of
cases and A is present in 11% (32). It is unclear why the
G to A mutation at the last nucleotide of exon results in
different splicings, while exons normally containing A
at the last nucleotide can be cleaved correctly. These
observations suggest that although pairing to U1 small
nuclear RNA seems to be a requirement for splicing,
other factors may also exist which interfere with stabili-
zation of the U1 small nuclear RNA–59 splice site inter-
actions or to modulate accessibility of these sites.
According to the two-step splicing model, the G to A
substitution at the last nucleotide of exon 6 in our case
could be expected to result in accumulation of an ab-
normal transcription species with intron 6 unremoved
but correctly spliced elsewhere. Such a species was not
observed in our case and in all of the eight cases re-
ported so far. Akli et al. (35) explained that due to the
large length of intron 5 (1.5 kb) of the b-hexosamini-
dase a subunit gene, the putative intron 5 retaining
Fig. 6. Scheme of the complementarity of the 59 end of U1 snRNA to the 59 splice site region. A: con-
sensus 59 splice site. B: intron 6 59 splice site of the sterol 27-hydroxylase gene. The G to A mutation is in-
dicated by an arrow. G–C pairing is indicated by thick bars, A–U pairing by thin bars, and G–U pairing by
short bars.516 Journal of Lipid Research Volume 39, 1998
species mRNA does not cross the nucleus membrane
and is degraded in the nucleus. In our case, intron 6
was only 195 bp and the abnormal species retaining
intron 6 was also not observed. On the other hand, in-
tron unremoved mRNA species could be observed in
case of mutations occurred at the intronic 59 gt posi-
tions (14, 15).
We have described here the ﬁrst example that a G to
A mutation at the last nucleotide of exon 6 of the CYP
27 gene leads to differently spliced mRNA species in-
cluding correctly spliced full-length mRNA carrying the
mutation, exon 6 skipped mRNA and 39 terminal 88 bp
of exon 6 deleted-mRNA, due to the use of an activated
59 cryptic splice site in exon 6. The results provide a
new molecular basis for CTX and also novel informa-
tion on aberrant splicing in multi-exon genes.
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